Drug Profile
Ipatasertib - Genentech
Alternative Names: GCD 0068; GDC-0068; RG-7440; RO 5532961Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Big Ten Cancer Research Consortium; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Roche; Roche Farma; SOLTI Breast Cancer Research Group
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Heterocyclic bicyclo compounds; Ketones; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Phase II Gastrointestinal cancer; Ovarian cancer; Solid tumours
- Phase I/II Endometrial cancer; Prostate cancer
- No development reported HER2 positive breast cancer
Most Recent Events
- 02 Mar 2024 Hoffmann-La Roche terminates the phase-III IPATunity150 trial in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, Brazil, Canada, Japan, Spain, South Korea, UK and USA (PO), based on a strategic sponsor decision and not driven by any safety concerns (NCT04060862)
- 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory) in Georgia (PO)